Publications

5891 Results

Final Results from S2302—PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (RP) versus standard of care (SOC) for participants (pts) previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC).

Authors
Reckamp KL
Journal / Conference
AACR Annual Meeting 2026 (April 17-22, 2026, San Diego, CA); Abstract CT140
Year
2026
Research Committee(s)
Lung
Study Number(s)
S2302

SWOG S2414 (INSIGHT): A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants with Early-Stage Non-Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting

Authors
Cetnar J;Zhao Y;Osarogiagbon RU;Pellini B;Boyle TA;Trejo Bittar HE;Dacic S;Hesketh PJ;Gunturu KS;Hsieh MH;Unger JM;Owen DH;Suga JM;Gelblum DY;Hirsch FR;Gray JE
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); TIP TPS8131 poster; doi: 10.1200/JCO.2026.44.16_suppl.TPS8131
Year
2026
Research Committee(s)
Lung
Study Number(s)
S2414

A Randomized Phase II Study of Capmatinib plus Osimertinib with or without Ramucirumab in Patients with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study S1900G)

Authors
Goldberg S
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); TIP TPS8677 poster
Year
2026
Research Committee(s)
Lung
Study Number(s)
S1900G

Immune-Related Adverse Event Severity and Clinical Outcomes with Immune Checkpoint Inhibitor Immunotherapy in Participants with Non–Small Cell Lung Cancer: Analysis of the Lung MAP sub-studies S1400A, S1400I, S1400F, and S1800A

Authors
Tseng D;Moon J;Bazhenova L;Leighl NB;Borghaei H;Dragnev KH;Baik CS;Langer CJ;Neal JW;Gandara DR;Kelly K;Gray JE;Herbst RS;Waqar SN
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 8572 poster
Year
2026
Research Committee(s)
Lung
Study Number(s)
S1400A, S1400F, S1400I, S1800A

A Phase II study of amivantamab hyaluronidase in MET amplification-positive stage IV or recurrent non-small cell lung cancer (Lung-MAP Sub-Study)

Authors
Rolfo C
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs TPS8680 TIP poster
Year
2026
Research Committee(s)
Lung
Study Number(s)
S1900J

Simplified Trials, Broader Reach: Lessons from SWOG S2302 Pragmatica-Lung

Authors
Kahlil M
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); pub only e23016 WITHDRAWN
Year
2026
Research Committee(s)
Lung
Study Number(s)
S2302

The Association of Baseline Fatigue and Severe Cancer Treatment Toxicity Persists by Comorbid Conditions: A Pooled Analysis

Authors
Caplan M;Unger JM;Till C;Fisch MJ;Henry NL;Accordino MK;Hershman DL
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il);
abs 11036 poster
Year
2026

Prevalence and Trends in Rural Patient Enrollment in SWOG Cancer Clinical Trials, 1992-2022

Authors
Okado I;Till C;Osarogiagbon RU;Doolittle GC;Hershman DL;Unger JM
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il);
abs 11068 poster
Year
2026
Research Committee(s)
Cancer Care Delivery

Clinical, Sociodemographic, Geographic, and Health Contributors to Variation in Overall Survival Across Randomized Cancer Trials

Authors
Unger JM;Till C;Osarogiagbon RU;Hershman DL;LeBlanc ML
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il);
pub only e23080 WITHDRAWN
Year
2026
Research Committee(s)
Cancer Care Delivery

A Risk Prediction Model for Severe, Life-Threatening, and Fatal Treatment-Related Toxicity

Authors
Unger JM;Henry NL;Fisch MJ;Hershman DL
Journal / Conference
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 12143 poster
Year
2026